Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

(NASDAQ:KOD) Kodiak Sciences Inc. reported recent business highlights and financial results for the second quarter ended June 30, 2026. Kodiak ended the second quarter of 2026 with $125.9 million of cash and cash equivalents. Net loss for the second quarter of 2026 was $65.6 million, or $1.05 per share on a basic and diluted basis. Research and development (R&D) expenses were $56.1 million for the second quarter of 2026. General and administrative (G&A) expenses were $10.8 million for the second quarter of 2026. Kodiak completed enrollment of the first 300-patient cohort supporting Pivotal Analysis 1 of the Phase 3 PEAK study. The company remains on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD.

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

(NASDAQ:KOD) Kodiak Sciences Inc. announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). The ALTO trial is designed to demonstrate the superiority of bispecific (anti-VEGF, anti-IL-6) KSI-501 versus monospecific (anti-VEGF) aflibercept in patients with DME. Approximately 910 patients will be randomized 5:3:5 to one of three arms in the ALTO Study (KSMP002-S1). The primary endpoint is the mean change in best-corrected visual acuity from baseline to the average of Week 48 and Week 52. The key secondary endpoint is the proportion of patients improving two or more steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at Week 48. Participants will be treated and followed for approximately 96 weeks. Topline data for the one-year primary endpoint in the DAYBREAK study are expected in September 2026.

Kodal Minerals — Bougouni Lithium Project Quarterly Update

(AIM: KOD) Kodal Minerals plc reported quarterly production of 26,174 dry metric tonnes (DMT) of spodumene concentrate grading 5.34% Li2O at its Bougouni Lithium Project for the three months ended 30 June 2026. Year to date production reached 53,195 DMT of spodumene concentrate, and a third shipment of approximately 20,400 DMT arrived at Hainan port on 27 June 2026, bringing total completed exports to over 69,000 tonnes. The price for the third shipment was calculated at US$2,304 per DMT, with an interim payment of $34.4 million already received for 95% of the estimated final value. LMLB, the mining operator, made an initial US$13 million repayment to KMUK for loans advanced to finance capital expenditure. Mining at the Ngoualana open pit yielded 2,232,687 total tonnes mined for the quarter, with 312,087 ore tonnes at an average grade of 1.13% and a strip ratio of 6.15. The company projects that the Stage 2 Floatation plant is expected to commence operations in 2028 with a forecast output of 230ktpa Li₂O, and plans to continue regular exports of spodumene concentrate on a six week to two-month schedule with cargo loads of up to 15,000 and 20,000 DMT tonnes. The Bougouni operation reported zero LTI incidents and one MTI incident during the quarter, and the Phase Two development programme will continue during the year.

Final Results for the 9 months to 31 December 2025

(NASDAQ:KOD) Kodal Minerals plc announced its audited final results for the nine months to 31 December 2025, reporting a group operating loss of £1,428,000 after impairments and share based payments. The Bougouni Lithium Project in Mali progressed from developer to critical metals producer in 12 months, with over 40,000 tonnes of concentrate produced by period end and a maiden shipment of 28,735 tonnes leaving the Port of San Pedro in November 2025. As of the announcement date, a total of over 69,000 tonnes of concentrate has been shipped and sold, generating US$89 million in revenue. The group invested £144,000 in exploration and evaluation expenditure on its gold projects, and the value of the Group's investment into KMUK was £20.6 million. Group net assets decreased by 4% to £43,669,000, and the cash balance was £14,875,000, a decrease of approximately 11.9% from the previous period. The company projects consistent delivery of the target of approximately 10,000 tonnes of spodumene concentrate per month for the first full year of production. Kodal Minerals also noted a US$15 million settlement payment made by KMUK under a Memorandum of Understanding with the State of Mali and ongoing arbitration proceedings regarding responsibility for this payment.

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Inc. (NASDAQ:KOD) reported its financial results for the third quarter ended March 31, 2026, highlighting positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy and ongoing progress in its late-stage clinical portfolio. The company reported a net loss of $58,158,000 for the quarter, with research and development expenses of $48,547,000. Cash and cash equivalents stood at $169,530,000 as of March 31, 2026. Key clinical milestones are anticipated in September and December 2026, with topline data readouts expected for several Phase 3 studies. These developments are significant as they may impact the company's pathway to regulatory submissions and future commercialization.

Gold Exploration - Nielle Licence Expiration

Kodal Minerals plc (AIM:KOD) announced that its licence for the Nielle gold concession in Côte d'Ivoire has expired, and the company no longer holds any continuing interest in that area. The Nielle Licence was initially granted in 2014 for three years, renewed twice for three-year terms, and received a further two-year exceptional renewal in 2023. A request for an additional exceptional renewal was not accepted. Kodal Minerals is the co-developer of the Bougouni Lithium Project in Southern Mali, which achieved first spodumene concentrate production in February 2025 and made its first shipment in December 2025. The Bougouni project covers 350km² and is operated by Les Mines de Lithium de Bougouni SA, with Kodal holding a 49 per cent shareholding.